Quintiles

Quintiles completes IPO of 27,236,841 shares of common stock

Wednesday, May 15, 2013 09:18 AM

Quintiles completed its initial public offering of 27,236,841 shares of its common stock at a price to the public of $40.00 per share.

More... »


Quintiles prices IPO at $40 per share

Thursday, May 9, 2013 11:40 AM

Quintiles has announced the pricing of its initial public offering of 23,684,210 shares of its common stock at a price to the public of $40.00 per share. The shares of Quintiles common stock are expected to begin trading on the New York Stock Exchange under the single-letter symbol "Q” on May 9, 2013.  

More... »


Quintiles wins Best CRO Award at World Vaccine Congress 2013

Friday, April 26, 2013 11:06 AM

For the second consecutive year, Quintiles has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress, the awards recognize and celebrate individuals, organizations and initiatives which have made significant contributions over the past 12 months.

More... »

Quintiles selects BRANY as U.S. Prime site

Monday, April 22, 2013 11:48 AM

BRANY (Biomedical Research Alliance of New York) has been designated a Quintiles Prime Site. The designation will advance BRANY’s participation in clinical trials by providing improved access to new industry-sponsored clinical trials.

More... »

BMS selects Quintiles as preferred central laboratory provider

Tuesday, April 16, 2013 10:06 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has been chosen as a preferred provider by Bristol-Myers Squibb to provide global support for BMS's central lab work, biomarker testing and assay development for the next five years.

More... »

Quintiles digital properties win two Web Marketing Assoc. awards

Thursday, April 4, 2013 08:00 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has received further recognition for the company’s digital communications with two “Internet Advertising Competition” (IAC) awards: one for its corporate website, Quintiles.com, and one for its patient education site, ClinicalResearch.com.

More... »

The CenterWatch Monthly, March 2013

Friday, March 1, 2013 08:00 AM

Sites rate the best sponsors 2013

More... »

Quintiles files registration statement for IPO

Friday, February 15, 2013 05:03 PM

Quintiles Transnational Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

More... »

Cardiome selects Quintiles to manage global regulatory affairs for Brinavess

Monday, February 11, 2013 10:22 AM

Biopharmaceutical company Cardiome Pharma has selected Quintiles, a global provider of biopharmaceutical services, to provide comprehensive post-marketing lifecycle safety and global regulatory affairs services for Brinavess (vernakalant intravenous). Quintiles will begin providing these services effective immediately as Cardiome continues to prepare for the anticipated transfer of Brinavess from Merck to Cardiome.

More... »

Synteract appoints Kelson as CFO, Doren as vice president of biometrics

Wednesday, January 30, 2013 03:18 PM

Synteract, a full service CRO based in Carlsbad, Calif., has hired new executives to support customers on a global scale. Keith Kelson will serve as chief financial officer and member of its executive council, and Phil Doren has been appointed vice president of biometrics.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs